ClinicalTrials.gg
RecruitingNCT07558538Updated Jun 11, 2026

A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome

An Early Phase 1 interventional study of Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder) in ARDS (Moderate or Severe) and ARDS (Acute Respiratory Distress Syndrome), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Shanghai Zhongshan Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.

Planned enrollment
107th of 132
24 · median 93
Started
2026
with 21 others
Phase 1
20 of 147
10 open now
Primary completion
2026-11
later than 22 of 87 live
Registered
136th of 147
by date

Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 107th largest by planned enrollment of the 132 interventional ones that give a count, is one of 22 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 22 of the 87 other live ones, and was the 136th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoma, Follicular with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, blank-controlled, open-label, single-dose, dose-escalation clinical study of rhKGF-2 in patients with ARDS.

The trial is designed with three dose groups (5 mg, 10 mg, and 15 mg), which will be escalated sequentially from the lowest dose group to the highest dose group. Each dose group will enroll 8 subjects, randomized in a 6:2 ratio according to the order of enrollment, to receive either the corresponding dose of rhKGF-2 (6 subjects) or serve as a blank control (2 subjects). Each subject will receive a single dose, administered once via a disposable bronchoscopic catheter.

All subjects will receive the trial intervention on top of standard ARDS treatment (see Concomitant Medications for details). Following the completion of drug administration, subjects will enter a 28-day follow-up period. Outcome measures include adverse events (AE), vital signs, laboratory parameters, oxygenation index (PFR), chest imaging changes, etc., to evaluate the safety, tolerability, and efficacy of the treatment.

03

Conditions studied

  • ARDS (Moderate or Severe)
  • ARDS (Acute Respiratory Distress Syndrome)

Keywords

  • ARDS (Acute Respiratory Distress Syndrome)
  • rh-KGF2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years and \<80 years, male or female.
  2. Definite diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition.
  3. Patients with PaO₂/FiO₂ \< 200 mmHg and receiving invasive mechanical ventilation via endotracheal intubation.
  4. Diagnosis of ARDS confirmed no more than 72 hours prior to enrollment.
  5. No plan for parenthood within 1 year and agree to take effective measures during the study period. Female participants of must have a negative serum pregnancy test.
  6. The subject fully understands the purpose of the study, as well as the nature, methods, and potential reactions of the drug. The subject voluntarily signs the form to participate in the study and agrees to comply with the requirements of the study protocol. If the subject is unable to provide consent or has limited capacity to consent, consent must be obtained from the subject's legal guardian.

    -

Exclusion criteria

Exclusion Criteria:

  1. Use of inhaled pulmonary vasodilators (e.g., nitric oxide or prostaglandins).
  2. Current receipt or planned receipt of extracorporeal membrane oxygenation (ECMO) during the study period.
  3. Expected survival \< 3 months due to causes other than respiratory failure.
  4. Cerebrovascular or cardiovascular events within 3 months prior to study drug administration, including unstable angina, congestive heart failure, myocardial infarction within the past 12 months, hemodynamic instability, known (LVEF) \< 40%, or arrhythmia or conduction abnormality.
  5. Inability to tolerate single-use bronchoscopic imaging catheter examination, including but not limited to the following: active massive hemoptysis; severe hypertension and arrhythmia; myocardial infarction or unstable angina within 4-6 weeks prior to screening; severe cardiac dysfunction; uncorrectable bleeding tendency ( count \< 60 × 10⁹/L), such as severe coagulation disorders, uremia, or severe pulmonary hypertension; severe superior vena cava syndrome; suspected aortic aneurysm; multiple pulmonary bullae.
  6. History of severe allergic reaction, or known allergy or to any component of the product.
  7. Breastfeeding or pregnant women.
  8. Participation in any drug clinical trial within 3 months prior to enrollment.
  9. Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    5 mg rhKGF-2

    Drug: Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)

  • No intervention
    Blank Control for 5 mg Cohort
  • Experimental
    10 mg rhKGF-2

    Drug: Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)

  • No intervention
    Blank Control for 10 mg Cohort
  • Experimental
    15 mg rhKGF-2

    Drug: Recombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)

  • No intervention
    Blank Control for 15 mg Cohort

Interventions

  • DrugRecombinant Human Keratinocyte Growth Factor-2 for Inhalation (Lyophilized Powder)

    The investigational drug will be reconstituted with water for injection to a concentration of 1 mg/mL, and then administered via a single-use bronchoscopic imaging catheter.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AE) and incidence of adverse drug reactions (ADR);

    Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

  2. Incidence of serious adverse events (SAE)

    Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

  3. Various laboratory test parameters:White blood cell (WBC) count

    Unit of measure: 3.5 - 9.5 × 10\^9/L

    Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

  4. Various Laboratory test parameters: Serum creatinine (Cr) level

    Unit of measure: 44 -115 μmol/L

    Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

  5. Various laboratory test parameters: Total Bilirubin

    Unit of measure: 3.4-20.4 umol /L

    Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

  6. Incidence of airway spasm (increased airway resistance) caused by local drug stimulation

    Time frame: At Baseline, Day 1, Day 2, Day 3, Day 5, Day 7, Day 14 and Day 28.

Secondary outcomes

  1. Improvement rate of oxygenation indexPaO₂/FiO₂ ratio (PFR)

    Time frame: at Day 3 and Day 7

  2. PaO₂/FiO₂ ratio (PFR) and its change from baseline

    Time frame: at Day 3, Day 5, and Day 7

  3. Number of days from baseline to first PaO₂/FiO₂ ratio (PFR) > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours

    Time frame: From baseline to first PFR > 300 mmHg or liberation from mechanical ventilation for at least 12 consecutive hours

  4. Change from baseline in the Murray Lung Injury Score(LIS).

    Score (scale range: 0-4; higher scores indicate more severe lung injury)

    Time frame: at Day 7

  5. Change from baseline in Radiographic Assessment of Lung Edema (RALE) score;

    Score (scale range: 0-48; higher scores indicate a worse outcome);

    Time frame: at Day 3, Day 7, Day 14, and Day 28

  6. Proportion of patients with improvement in ARDS severity grade

    Time frame: at Day 7 and Day 14

  7. Proportion of patients with progression in ARDS severity grade

    Time frame: at Day 7 and Day 14

  8. All-cause mortality

    Time frame: at Day 28

  9. Systemic evaluation measures: Ventilator-free days at Day 28

    Ventilator-free days at Day 28 (unit: days; higher scores indicate a better outcome).

    Time frame: at Day 28

  10. Systemic evaluation measures: Non-ICU hospital stay days at Day 28

    Non-ICU hospital stay days at Day 28 (unit: days; higher scores indicate a better outcome as applicable).

    Time frame: at Day 28.

  11. Systemic evaluation measures: Non-hospitalization days at Day 28

    Non-hospitalization days at Day 28 (unit: days; higher scores indicate a better outcome).

    Time frame: at Day 28

07

Study locations

1 of 1 sites recruiting
  • ShanghaiZhongshan
    Shanghai, Shanghai Municipality 200000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Informed consent form

Time frame: Sharing will begin within 6 months after article publication.

Access criteria: IPD and supporting information will be avaible to researchers upon reasonable request (e.g. with a practical and meaningful research proposal).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 89 non-industry phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 6 months is below that.

Counting every sponsor, half of 174 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2026
First posted
Apr 30, 2026
StartActual
May 14, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07558538
Responsible party
Song Yuanlin (Director of Department of Pulmonary and Critical Care Medicine, Shanghai Zhongshan Hospital) — Principal investigator
First posted
Apr 30, 2026
Start date
May 14, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 11, 2026

Study contacts

Yi Wei
Contact
yiwei4075@163.com
+86 18872984075
Yuanlin Song
study director · Shanghai Zhongshan Hospital
Jing Bi
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion